CHS 8 Cumulative Redeemable Pref Shs Financials

CHSCP

Source SEC Filings (10-K/10-Q) Data as of May 31, 2026 Currency USD FYE August

This page shows CHS 8 Cumulative Redeemable Pref Shs (CHSCP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CHSCP FY2025 2026-04-22

Razor-thin spreads make CHS a volume business, and FY2025 shows how quickly core profit can erode.

From FY2023 to FY2025, operating margin fell from 3.0% to 0.3%, showing that a small loss of spread or cost absorption can dramatically weaken the core engine. In FY2025, operating income of $91M sat below interest expense of $146M, yet net income stayed positive while free cash flow turned negative, so reported earnings looked sturdier than operating cash economics.

Even at FY2023's peak, gross margin was only 5.2%; by FY2025 it was 3.2%. That margin shape says the company mostly moves a lot of dollars for a small spread, so modest compression in spread or overhead absorption hits operating profit disproportionately rather than gradually.

The balance-sheet posture is still restrained rather than debt-driven: debt to equity eased to 0.2x and the current ratio stayed near 1.5x, while equity kept building as liabilities drifted down. The pressure point is cash conversion; operating cash flow of $636M did not cover capex of $729M, which is why free cash flow turned negative.

Financial Health Signals

Financial Health Score 34/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of CHS 8 Cumulative Redeemable Pref Shs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

CHS 8 Cumulative Redeemable Pref Shs has an operating margin of 0.3%, meaning the company retains $0 of operating profit per $100 of revenue. This results in a moderate score of 42/100, indicating healthy but not exceptional operating efficiency. This is down from 1.5% the prior year.

Growth

CHS 8 Cumulative Redeemable Pref Shs's revenue declined 9.7% year-over-year, from $39.3B to $35.5B. This contraction results in a growth score of 9/100.

Leverage

CHS 8 Cumulative Redeemable Pref Shs has a moderate D/E ratio of 0.16. This balance of debt and equity financing earns a leverage score of 32/100.

Liquidity

CHS 8 Cumulative Redeemable Pref Shs's current ratio of 1.53 indicates adequate short-term liquidity, earning a score of 41/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While CHS 8 Cumulative Redeemable Pref Shs generated $635.8M in operating cash flow, capex of $728.6M consumed most of it, leaving -$92.8M in free cash flow. This results in a low score of 33/100, reflecting heavy capital investment rather than weak cash generation.

Returns

CHS 8 Cumulative Redeemable Pref Shs's ROE of 5.4% shows moderate profitability relative to equity, earning a score of 45/100. This is down from 10.3% the prior year.

Piotroski F-Score Partial

4/8

CHS 8 Cumulative Redeemable Pref Shs passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

1.06x

For every $1 of reported earnings, CHS 8 Cumulative Redeemable Pref Shs generates $1.06 in operating cash flow ($635.8M OCF vs $597.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

0.6x

CHS 8 Cumulative Redeemable Pref Shs earns $0.6 in operating income for every $1 of interest expense ($90.8M vs $146.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$35.5B

YoY-9.7%

5Y CAGR+4.5%

10Y CAGR+0.3%

CHS 8 Cumulative Redeemable Pref Shs generated $35.5B in revenue in fiscal year 2025. This represents a decrease of 9.7% from the prior year.

EBITDA

$742.2M

YoY-35.7%

5Y CAGR-0.3%

10Y CAGR-3.6%

CHS 8 Cumulative Redeemable Pref Shs's EBITDA was $742.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 35.7% from the prior year.

Net Income

$597.9M

YoY-45.8%

5Y CAGR+7.2%

10Y CAGR-2.6%

CHS 8 Cumulative Redeemable Pref Shs reported $597.9M in net income in fiscal year 2025. This represents a decrease of 45.8% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$92.8M

YoY-120.0%

CHS 8 Cumulative Redeemable Pref Shs generated -$92.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 120.0% from the prior year.

Cash & Debt

$327.8M

YoY-58.8%

5Y CAGR+18.4%

10Y CAGR-10.3%

CHS 8 Cumulative Redeemable Pref Shs held $327.8M in cash against $1.7B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

CHS 8 Cumulative Redeemable Pref Shs had 0 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

3.2%

YoY-1.3pp

5Y CAGR-0.3pp

10Y CAGR-1.1pp

CHS 8 Cumulative Redeemable Pref Shs's gross margin was 3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the prior year.

Operating Margin

0.3%

YoY-1.2pp

5Y CAGR-0.7pp

10Y CAGR-1.8pp

CHS 8 Cumulative Redeemable Pref Shs's operating margin was 0.3% in fiscal year 2025, reflecting core business profitability. This is down 1.2 percentage points from the prior year.

Net Margin

1.7%

YoY-1.1pp

5Y CAGR+0.2pp

10Y CAGR-0.6pp

CHS 8 Cumulative Redeemable Pref Shs's net profit margin was 1.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.1 percentage points from the prior year.

Return on Equity

5.4%

YoY-4.8pp

5Y CAGR+0.6pp

10Y CAGR-4.8pp

CHS 8 Cumulative Redeemable Pref Shs's ROE was 5.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.8 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$728.6M

YoY-9.9%

5Y CAGR+11.7%

10Y CAGR-4.8%

CHS 8 Cumulative Redeemable Pref Shs invested $728.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 9.9% from the prior year.

CHSCP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$35.5B-9.7%	$39.3B-13.9%	$45.6B-4.6%	$47.8B+24.3%	$38.4B+35.4%	$28.4B
Cost of Revenue	$34.3B-8.5%	$37.5B-13.2%	$43.2B-5.4%	$45.7B+21.8%	$37.5B+36.7%	$27.4B
Gross Profit	$1.1B-35.1%	$1.8B-26.3%	$2.4B+11.7%	$2.1B+123.6%	$951.4M-3.1%	$981.8M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.0B-10.4%	$1.2B+13.0%	$1.0B+3.5%	$997.8M+33.8%	$745.6M+5.8%	$704.5M
Operating Income	$90.8M-84.5%	$584.4M-56.5%	$1.3B+19.0%	$1.1B+448.6%	$205.8M-25.8%	$277.3M
Interest Expense	$146.1M+40.4%	$104.1M-24.3%	$137.4M+20.4%	$114.2M+9.2%	$104.6M-10.6%	$117.0M
Income Tax	$16.8M+444.4%	-$4.9M-104.5%	$107.7M-18.5%	$132.1M+445.4%	-$38.2M-4.1%	-$36.7M
Net Income	$597.9M-45.8%	$1.1B-42.0%	$1.9B+13.2%	$1.7B+203.1%	$554.0M+31.1%	$422.4M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$11.6B+38.6%	$8.4B-5.8%	$8.9B+3.0%	$8.6B-11.9%	$9.8B+25.3%	$7.8B-16.1%	$9.3B+1.3%	$9.2B
Cost of Revenue	$11.2B+34.1%	$8.3B-1.7%	$8.5B+2.4%	$8.3B-12.3%	$9.4B+22.2%	$7.7B-13.2%	$8.9B-0.1%	$8.9B
Gross Profit	$410.6M+1490.4%	$25.8M-93.4%	$389.4M+18.0%	$330.0M+0.1%	$329.8M+332.2%	$76.3M-81.0%	$400.7M+46.9%	$272.7M
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$302.3M+13.0%	$267.6M-0.2%	$268.1M-2.9%	$276.1M+6.7%	$258.9M+4.3%	$248.3M-5.5%	$262.9M-12.5%	$300.2M
Operating Income	$108.3M+144.8%	-$241.8M-299.4%	$121.2M+124.8%	$53.9M-24.0%	$71.0M+141.3%	-$172.0M-224.8%	$137.8M+600.1%	-$27.6M
Interest Expense	$49.7M+13.6%	$43.8M+17.2%	$37.4M-24.0%	$49.1M+11.4%	$44.1M+75.0%	$25.2M-8.8%	$27.6M+8.2%	$25.6M
Income Tax	$14.7M+182.7%	-$17.8M-251.6%	$11.7M+178.6%	-$14.9M-155.0%	$27.2M+412.0%	-$8.7M-165.8%	$13.2M+150.4%	-$26.3M
Net Income	$267.4M+281.8%	-$147.1M-156.5%	$260.5M+32.4%	$196.7M-15.3%	$232.2M+406.5%	-$75.8M-130.9%	$244.8M+118.9%	$111.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CHSCP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$18.9B+0.8%	$18.7B-1.3%	$19.0B+0.7%	$18.8B+7.1%	$17.6B+9.9%	$16.0B
Current Assets	$8.1B-7.1%	$8.7B-4.6%	$9.1B-2.7%	$9.4B+17.2%	$8.0B+27.6%	$6.3B
Cash & Equivalents	$327.8M-58.8%	$794.9M-55.0%	$1.8B+122.3%	$794.0M+92.2%	$413.2M+193.3%	$140.9M
Inventory	$3.3B+6.6%	$3.1B-4.6%	$3.2B-12.0%	$3.7B+9.5%	$3.3B+21.6%	$2.7B
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$239.4M+33.0%	$180.0M0.0%	$180.0M0.0%	$180.0M+4.9%	$171.6M-0.5%	$172.4M
Total Liabilities	$7.8B-2.2%	$8.0B-6.5%	$8.5B-9.2%	$9.4B+9.4%	$8.6B+19.3%	$7.2B
Current Liabilities	$5.3B-2.2%	$5.4B-8.4%	$5.9B-15.1%	$7.0B+9.9%	$6.3B+28.6%	$4.9B
Long-Term Debt	$1.7B-4.3%	$1.8B+0.2%	$1.8B+9.1%	$1.7B+5.6%	$1.6B-1.4%	$1.6B
Total Equity	$11.1B+3.0%	$10.8B+2.9%	$10.4B+10.5%	$9.5B+5.0%	$9.0B+2.3%	$8.8B
Retained Earnings	$3.0B+7.5%	$2.8B+10.6%	$2.5B+23.4%	$2.1B+19.9%	$1.7B+5.9%	$1.6B

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$20.8B-0.6%	$20.9B+0.8%	$20.7B+10.0%	$18.9B-4.2%	$19.7B-2.1%	$20.1B+2.7%	$19.6B+4.6%	$18.7B
Current Assets	$9.9B-3.0%	$10.3B+3.6%	$9.9B+22.4%	$8.1B-9.4%	$8.9B-7.9%	$9.7B+3.6%	$9.4B+7.5%	$8.7B
Cash & Equivalents	$497.6M+100.3%	$248.5M-33.7%	$374.7M+14.3%	$327.8M+1.2%	$323.9M-25.3%	$433.3M-3.8%	$450.5M-43.3%	$794.9M
Inventory	$3.6B-26.2%	$4.9B+12.9%	$4.3B+32.3%	$3.3B-5.2%	$3.5B-25.7%	$4.6B+19.0%	$3.9B+27.2%	$3.1B
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$239.4M	N/A	N/A	N/A	$180.0M
Total Liabilities	$9.6B-2.8%	$9.9B+3.3%	$9.5B+22.5%	$7.8B-12.5%	$8.9B-5.2%	$9.4B+7.2%	$8.8B+10.1%	$8.0B
Current Liabilities	$6.8B-4.4%	$7.1B+1.6%	$7.0B+31.9%	$5.3B-16.9%	$6.4B-6.2%	$6.8B+11.8%	$6.1B+12.4%	$5.4B
Long-Term Debt	$2.0B0.0%	$2.0B+14.0%	$1.7B-0.3%	$1.7B-4.4%	$1.8B-0.1%	$1.8B+0.4%	$1.8B-0.1%	$1.8B
Total Equity	$11.2B+1.3%	$11.1B-1.3%	$11.2B+1.1%	$11.1B+2.7%	$10.8B+0.7%	$10.7B-1.0%	$10.8B+0.5%	$10.8B
Retained Earnings	$3.2B+6.3%	$3.0B-5.7%	$3.2B+4.9%	$3.0B-0.1%	$3.0B+6.5%	$2.8B-3.0%	$2.9B+4.1%	$2.8B

CHSCP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$635.8M-50.1%	$1.3B-61.2%	$3.3B+68.7%	$1.9B+156.9%	$757.8M-30.3%	$1.1B
Capital Expenditures	$728.6M-9.9%	$808.8M+43.3%	$564.5M+59.3%	$354.4M+11.5%	$317.8M-24.0%	$418.4M
Free Cash Flow	-$92.8M-120.0%	$464.1M-82.9%	$2.7B+70.8%	$1.6B+261.8%	$440.0M-34.2%	$668.9M
Investing Cash Flow	-$880.6M+38.5%	-$1.4B-50.7%	-$950.2M-107.9%	-$457.1M-349.6%	-$101.7M+58.3%	-$243.7M
Financing Cash Flow	-$230.6M+71.7%	-$814.3M+41.7%	-$1.4B-25.3%	-$1.1B-241.0%	-$326.6M+64.9%	-$931.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	$1.1B+294.7%	-$569.0M-68.4%	-$337.8M-126.6%	$1.3B+82.5%	$696.6M+167.1%	-$1.0B-253.0%	-$294.0M-126.4%	$1.1B
Capital Expenditures	$123.3M+17.5%	$105.0M-9.5%	$116.0M-40.5%	$195.1M+10.9%	$175.9M+6.7%	$164.9M-14.4%	$192.7M-27.9%	$267.4M
Free Cash Flow	$984.7M+246.1%	-$674.0M-48.5%	-$453.8M-142.2%	$1.1B+106.7%	$520.6M+143.3%	-$1.2B-147.1%	-$486.6M-157.5%	$845.8M
Investing Cash Flow	-$298.4M-800.4%	$42.6M+117.2%	-$247.9M+24.5%	-$328.4M+35.1%	-$506.3M-1191.0%	-$39.2M-488.2%	-$6.7M+99.3%	-$912.1M
Financing Cash Flow	-$525.2M-234.0%	$392.1M-39.1%	$644.2M+167.4%	-$955.3M-210.7%	-$307.5M-128.8%	$1.1B+3063.8%	-$36.0M-112.8%	$281.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CHSCP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	3.2%-1.3pp	4.5%-0.8pp	5.2%+0.8pp	4.5%+2.0pp	2.5%-1.0pp	3.5%
Operating Margin	0.3%-1.2pp	1.5%-1.5pp	2.9%+0.6pp	2.4%+1.8pp	0.5%-0.4pp	1.0%
Net Margin	1.7%-1.1pp	2.8%-1.4pp	4.2%+0.7pp	3.5%+2.1pp	1.4%-0.1pp	1.5%
Return on Equity	5.4%-4.8pp	10.3%-7.9pp	18.2%+0.4pp	17.8%+11.6pp	6.2%+1.3pp	4.8%
Return on Assets	3.2%-2.7pp	5.9%-4.1pp	10.0%+1.1pp	8.9%+5.8pp	3.1%+0.5pp	2.6%
Current Ratio	1.53-0.1	1.61+0.1	1.55+0.2	1.35+0.1	1.260.0	1.27
Debt-to-Equity	0.16-0.0	0.170.0	0.170.0	0.180.0	0.180.0	0.18
FCF Margin	-0.3%-1.4pp	1.2%-4.8pp	6.0%+2.6pp	3.3%+2.2pp	1.1%-1.2pp	2.4%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	3.5%+3.2pp	0.3%-4.1pp	4.4%+0.6pp	3.8%+0.5pp	3.4%+2.4pp	1.0%-3.3pp	4.3%+1.3pp	3.0%
Operating Margin	0.9%+3.8pp	-2.9%-4.3pp	1.4%+0.7pp	0.6%-0.1pp	0.7%+2.9pp	-2.2%-3.7pp	1.5%+1.8pp	-0.3%
Net Margin	2.3%+4.1pp	-1.8%-4.7pp	2.9%+0.6pp	2.3%-0.1pp	2.4%+3.4pp	-1.0%-3.6pp	2.6%+1.4pp	1.2%
Return on Equity	2.4%+3.7pp	-1.3%-3.7pp	2.3%+0.6pp	1.8%-0.4pp	2.1%+2.9pp	-0.7%-3.0pp	2.3%+1.2pp	1.0%
Return on Assets	1.3%+2.0pp	-0.7%-2.0pp	1.3%+0.2pp	1.0%-0.1pp	1.2%+1.6pp	-0.4%-1.6pp	1.3%+0.7pp	0.6%
Current Ratio	1.47+0.0	1.45+0.0	1.42-0.1	1.53+0.1	1.40-0.0	1.43-0.1	1.54-0.1	1.61
Debt-to-Equity	0.180.0	0.18+0.0	0.160.0	0.16-0.0	0.170.0	0.170.0	0.170.0	0.17
FCF Margin	8.5%+16.6pp	-8.1%-2.9pp	-5.1%-17.6pp	12.5%+7.2pp	5.3%+20.8pp	-15.4%-10.2pp	-5.2%-14.5pp	9.2%

Similar Companies

FORAFRIC GLOBAL PLC AFRIW

Agriforce AGRIW

EDIBLE GARDEN AG INC EDBLW

Sadot Group SDOT

$18.5M

Agriforce Growing Systems Ltd AGRI

$9.6M

Frequently Asked Questions

What is CHS 8 Cumulative Redeemable Pref Shs's annual revenue?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) reported $35.5B in total revenue for fiscal year 2025. This represents a -9.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CHS 8 Cumulative Redeemable Pref Shs's revenue growing?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) revenue declined by 9.7% year-over-year, from $39.3B to $35.5B in fiscal year 2025.

Is CHS 8 Cumulative Redeemable Pref Shs profitable?

Yes, CHS 8 Cumulative Redeemable Pref Shs (CHSCP) reported a net income of $597.9M in fiscal year 2025, with a net profit margin of 1.7%.

What is CHS 8 Cumulative Redeemable Pref Shs's EBITDA?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had EBITDA of $742.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does CHS 8 Cumulative Redeemable Pref Shs have?

As of fiscal year 2025, CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had $327.8M in cash and equivalents against $1.7B in long-term debt.

What is CHS 8 Cumulative Redeemable Pref Shs's gross margin?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had a gross margin of 3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is CHS 8 Cumulative Redeemable Pref Shs's operating margin?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had an operating margin of 0.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is CHS 8 Cumulative Redeemable Pref Shs's net profit margin?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had a net profit margin of 1.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is CHS 8 Cumulative Redeemable Pref Shs's return on equity (ROE)?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) has a return on equity of 5.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CHS 8 Cumulative Redeemable Pref Shs's free cash flow?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) generated -$92.8M in free cash flow during fiscal year 2025. This represents a -120.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CHS 8 Cumulative Redeemable Pref Shs's operating cash flow?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) generated $635.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are CHS 8 Cumulative Redeemable Pref Shs's total assets?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had $18.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are CHS 8 Cumulative Redeemable Pref Shs's capital expenditures?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) invested $728.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does CHS 8 Cumulative Redeemable Pref Shs have outstanding?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had 0 shares outstanding as of fiscal year 2025.

What is CHS 8 Cumulative Redeemable Pref Shs's current ratio?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had a current ratio of 1.53 as of fiscal year 2025, which is generally considered healthy.

What is CHS 8 Cumulative Redeemable Pref Shs's debt-to-equity ratio?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CHS 8 Cumulative Redeemable Pref Shs's return on assets (ROA)?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) had a return on assets of 3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CHS 8 Cumulative Redeemable Pref Shs's Piotroski F-Score?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CHS 8 Cumulative Redeemable Pref Shs's earnings high quality?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) has an earnings quality ratio of 1.06x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CHS 8 Cumulative Redeemable Pref Shs cover its interest payments?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) has an interest coverage ratio of 0.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is CHS 8 Cumulative Redeemable Pref Shs?

CHS 8 Cumulative Redeemable Pref Shs (CHSCP) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.